Compare CIM & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CIM | ABCL |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2007 | 2020 |
| Metric | CIM | ABCL |
|---|---|---|
| Price | $12.48 | $3.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $15.25 | $7.75 |
| AVG Volume (30 Days) | 823.7K | ★ 3.2M |
| Earning Date | 02-11-2026 | 11-06-2025 |
| Dividend Yield | ★ 11.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $191,573,000.00 | $35,325,000.00 |
| Revenue This Year | $11.44 | $25.45 |
| Revenue Next Year | $21.50 | $10.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 7.17 |
| 52 Week Low | $9.85 | $1.89 |
| 52 Week High | $15.37 | $6.52 |
| Indicator | CIM | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 57.83 |
| Support Level | $12.30 | $3.34 |
| Resistance Level | $12.81 | $3.82 |
| Average True Range (ATR) | 0.25 | 0.20 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 26.03 | 95.75 |
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.